1. Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study
- Author
-
Simone van de Sande-Lee, Sylka Rodovalho, Celso Dario Ramos, Licio A. Velloso, Jose C. de-Lima-Junior, Milena Monfort-Pires, Fernando Cendes, B. Rachid, Riobaldo M. R. Cintra, and Franco Folli
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Glucose uptake ,Hypothalamus ,030209 endocrinology & metabolism ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Proof of Concept Study ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Insulin resistance ,Adipose Tissue, Brown ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Internal medicine ,Diabetes mellitus ,Brown adipose tissue ,Internal Medicine ,Humans ,Medicine ,Gliosis ,Obesity ,Thiazolidinedione ,Aged ,Pioglitazone ,business.industry ,Hypothalamic gliosis ,Organ Size ,General Medicine ,Middle Aged ,Overweight ,medicine.disease ,medicine.anatomical_structure ,Diabetes Mellitus, Type 2 ,Drug Therapy, Combination ,Female ,Thiazolidinediones ,business ,medicine.drug - Abstract
This study aimed to evaluate the effect of pioglitazone on brown adipose tissue function and hypothalamic gliosis in humans. Brown adipose tissue and the hypothalamus are regarded as important potential pharmacological targets to metabolic diseases, and defining the impact of current therapies on their structure and/or function could provide therapeutic advance in this field. Six patients with type 2 diabetes were treated for 24 weeks with pioglitazone 30 mg/day as an add-on therapy. Brown adipose tissue glucose uptake and volume were determined using 18F-FDG PET/CT scans; hypothalamic gliosis was determined using MRI scans; blood was collected for hormone and biochemistry measurements. All tests were performed at inclusion and six months after pioglitazone introduction. Pioglitazone treatment led to a significant 3% body mass increase. There were neither changes in cold-induced brown adipose tissue glucose uptake and volume nor changes in hypothalamic gliosis. This is a proof-of-concept study that provides clinical evidence for a lack of action of a thiazolidinedione, pioglitazone, to promote homogeneous and measurable changes in brown adipose tissue volume and also in hypothalamic gliosis after 6 months of treatment.
- Published
- 2019
- Full Text
- View/download PDF